Caliprazine impuritiesA
|
卡利拉嗪杂质A
|
|
Raxicept sodium impurity 3
|
拉氧头孢钠杂质3
|
|
Macitentan Impurity 42
|
马西替坦杂质42
|
|
L-salbutamol impurity B
|
左旋沙丁胺醇杂质B(指定BP 852)
|
|
Aminobenzimidazole impurity 5
|
氨基苯并咪唑杂质5
|
|
Dipropivacaine Impurity 5
|
利丙双卡因杂质5
|
|
Melphalan lmpurity 7
|
美法仑杂质7
|
|
Melphalan lmpurity 5
|
美法仑杂质5
|
|
Mexiletine Impurity 19
|
美西律杂质19
|
68164-73-8
|
Nintedanib Impurity 32
|
尼达尼布杂质32
|
|
Mupirocin Impurity 5
|
莫匹罗星杂质5
|
|
Milbemycin EP impurities D
|
米尔贝霉素EP杂质D
|
|
Salbutamol impurity B (designated brand BP cat. No: 852)
|
沙丁胺醇杂质B(指定品牌BP 货号:852)
|
|
(2-hydroxy-2 - (3-hydroxyphenyl) ethyl) (methyl) amino) - 4-oxobuty-2-enoic acid
|
(2-羟基-2-(3-羟基苯基)乙基)(甲基)氨基)-4-氧代丁-2-烯酸
|
|
Carbiramine related compound C
|
卡比沙明相关化合物C(指定品牌USP 1096032)
|
|
Dipropivacaine Impurity 4
|
利丙双卡因杂质4
|
|
Raxicept sodium impurity 2
|
拉氧头孢钠杂质2
|
|
Chlorpromazine impurity D
|
氯丙嗪杂质D CRS(指定品牌EP Y0000479)
|
|
Mupirocin EP Impurity H
|
莫匹罗星EP杂质H
|
|
Mexiletine Impurity 18
|
美西律杂质18
|
26583-69-7
|
Fosinopril related compound B
|
福辛普利相关化合物B(指定品牌USP 1283426)
|
|
Ibuprofen Impurity 69(mixture)
|
布洛芬杂质69(混合物)
|
|
Tranexamic Acid Impurity F CRS(designated brand EP Y0002154)
|
氨甲环酸杂质F CRS(指定品牌EP Y0002154)
|
|
Ceftriaxone impurity 29(ene Isomer)
|
头孢曲松杂质29(烯异构体)
|
|
Aminobenzimidazole impurity4
|
氨基苯并咪唑杂质4
|
|
Lummakato impurities8
|
鲁玛卡托杂质8
|
|
Rifampicin impurities5
|
利福平杂质5
|
13292-53-0
|
Meloxicam EP Impurity A
|
美洛昔康EP杂质A(洛昔康杂质A对照品)
|
24683-26-9
|
N-(2-Quinoxaline)-sulfaquinoxalin.
|
N-(2-喹喔啉)-磺胺喹喔啉。
|
|
Ceftriaxone sodium impurity H
|
头孢曲松钠杂质H
|
|
1-nitroso-1H-benzotriazole
|
1-亚硝基-1H-苯并三唑
|
|
Impurity 1 of dapafinil mesylate
|
达帕菲尼甲磺酸盐杂质1
|
|
Aminobenzimidazole impurity1
|
氨基苯并咪唑杂质1
|
|
Antipyrine Impurity 8
|
安替比林杂质8
|
|
Mupirocin Impurity 6
|
莫匹罗星杂质6
|
|
Clindamycin Phosphate Impurity G
|
克林霉素磷酸酯杂质G
|
|
Nintedanib Impurity 41
|
尼达尼布杂质41
|
121-95-9
|
Tranexamic acid impurity F
|
氨甲环酸杂质F(指定品牌EP Y0002153)
|
|
Dexamethasone Impurity 24
|
地塞米松杂质24
|
14899-36-6
|
Amphotericin B Impurity E
|
两性霉素B杂质 E
|
|
Isoproterenol Impurity 27
|
异丙肾上腺素杂质27
|
|
Ataluren impurities2
|
阿塔鲁伦杂质2
|
|
Raxicept sodium impurity 4
|
拉氧头孢钠杂质4
|
|
Raxicept sodium impurity 1
|
拉氧头孢钠杂质1
|
|
Gefitinib Impurity 69
|
吉非替尼杂质69
|
|
Articaine Impurity 20
|
阿替卡因杂质20
|
47066-35-3
|
Leuprorelin EP Impurity K
|
亮丙瑞林EP杂质K
|
|
Siliconized microcrystalline cellulose
|
硅化微晶纤维素(指定USP货号:1098399)
|
|
Dydrogesterone Impurity 14
|
地屈孕酮杂质14
|
|
Losartan system suitability
|
洛沙坦系统适用性CRS
|
|
Penicillin sodium EPimpurity F
|
青霉素钠EP杂质F
|
|
Betamethasone bromide
|
溴代倍他米松
|
|
Benidipine Impurity I
|
贝尼地平杂质I
|
|
Non Sorodine Impurities2
|
非索罗定杂质2
|
|
Febuxostat Impurity 32
|
非布索坦杂质32
|
1805770-41-5
|
Tetracaine Impurity 3
|
丁卡因杂质3
|
94-14-4
|
Nintedanib Impurity 36
|
尼达尼布杂质36
|
|
Betaxolol impurity a
|
倍他洛尔杂质A(指定)
|
|
Lornoxicam Impurity 49
|
氯诺昔康杂质49
|
54166-60-8
|
Fosinopril related compound E
|
福辛普利相关化合物E(指定品牌USP?1283459)
|
|
Ceftriaxone impurity 30 (olefin isomer disodium salt)
|
头孢曲松杂质30(烯异构体二钠盐)
|
|
4-{4-fluoro-3-[(4-nitrosopiperazin-1-yl)carbonyl]benzyl}phthalazin-1(2H)-one
|
4-{4-氟-3-[(4-亚硝基哌嗪-1-基)羰基]苄基}酞嗪-1(2H)-酮
|
|
Impurity 2 of dapafinil mesylate
|
达帕菲尼甲磺酸盐杂质2
|
|
Aminobenzimidazole impurity2
|
氨基苯并咪唑杂质2
|
|
Nintedanib impurity 53
|
尼达尼布杂质53
|
1160293-22-0
|
Valsartan Impurity 3
|
缬沙坦杂质3
|
|
Oxacillin sodium EP Impurity F
|
苯唑西林钠EP杂质F
|
|
Nintedanib Impurity 46
|
尼达尼布杂质46
|
99846-70-5
|
Milbemycin EP impurities F
|
米尔贝霉素EP杂质F
|
|
Rifampicin impurities6
|
利福平杂质6
|
|
Milbemycin EP impurities I
|
米尔贝霉素EP杂质I
|
|
8s-isopropyl-3 β- Mm hydroxymethylammonium bromide
|
8s-异丙基-3β-羟基甲基溴化铵(指定BP 626)
|
|
Articaine Impurity 21
|
阿替卡因杂质21
|
|
Aminobenzimidazole
|
氨基苯并咪唑
|
|
Mexiletine Impurity 20
|
美西律杂质20
|
|
Nintedanib Impurity 33
|
尼达尼布杂质33
|
2186-92-7
|
Fosinopril related compound F
|
福辛普利相关化合物F(指定品牌USP?1283460)
|
|
Omeprazole Related Compound F and G Mixture
|
奥美拉唑相关物质F和G混合物 (货号1478491)
|
|
Lilalitine impurity 1
|
利拉利汀杂质1
|
|
Bepotastine Impurity 3
|
贝他斯汀杂质3
|
210095-66-2
|
Lornoxicam Impurity 50
|
氯诺昔康杂质50
|
106820-63-7
|
Nintedanib Impurity 35
|
尼达尼布杂质35
|
1895918-24-7
|
Nimesulide impurity D (control article)
|
尼美舒利杂质D(对照品)(指定EP货号:N0845008)
|
|
Dydrogesterone Impurity 15
|
地屈孕酮杂质15
|
|
Ethyl cinnamate impurity 1
|
肉桂酸乙酯杂质1
|
|
Dipropivacaine Impurity 2
|
利丙双卡因杂质2
|
|
ProMethazine EP IMpurity B(Phenothiazine EP impurityB)
|
盐酸异丙嗪EP杂质B(吩噻嗪EP杂质B)
|
|
Lapatinib Impurity 11
|
拉帕替尼杂质11
|
231278-83-4
|
Melphalan lmpurity 3
|
美法仑杂质3
|
896715-19-8
|
Ticargrelor impurity 7
|
替格瑞洛杂质7
|
2588537-76-0
|
Mupirocin EP Impurity G
|
莫匹罗星EP杂质G
|
|
Fosfomycin tromethamine Impurity5(Disodium Salt)
|
磷霉素氨丁三醇杂质5(二钠盐)
|
|
Ticagrelor system suitability for CRS
|
替卡格雷系统适用性CRS(指定)
|
|
Impurity 4 of dapafinil mesylate
|
达帕菲尼甲磺酸盐杂质4
|
|
Aminobenzimidazole impurity3
|
氨基苯并咪唑杂质3
|
|
Lummakato impurities6
|
鲁玛卡托杂质6
|
|
Melphalan lmpurity 6
|
美法仑杂质6
|
1951445-22-9
|
Meloxicam EP Impurity D
|
美洛昔康EP杂质D(美洛昔康杂质D对照品)
|
1331636-17-9
|
Cefmetazole Impurity 21
|
头孢美唑杂质21
|
|
Articaine Impurity 17
|
阿替卡因杂质17
|
2602451-78-3
|